Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

G. Gebhart; L. E. Lamberts; Z. Wimana; C. Garcia; P. Emonts; L. Ameye; S. Stroobants; M. Huizing; P. Aftimos; J. Tol; W. J. G. Oyen; D. J. Vugts; O. S. Hoekstra; C. P. Schroder; C. W. Menke-van der Houven van Oordt; T. Guiot; A. H. Brouwers; A. Awada; E. G. E. de Vries; P. Flamen

doi:https://doi.org/10.1093/annonc/mdv577

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

G. Gebhart, L. E. Lamberts, Z. Wimana, C. Garcia, P. Emonts, L. Ameye, S. Stroobants, M. Huizing, P. Aftimos, J. Tol, W. J. G. Oyen, D. J. Vugts, O. S. Hoekstra, C. P. Schroder, C. W. Menke-van der Houven van Oordt, T. Guiot, A. H. Brouwers, A. Awada, E. G. E. de Vries, P. Flamen

Research output: Contribution to journal › Article › Academic › peer-review

263 Citations (Scopus)

Original language	English
Pages (from-to)	619-624
Journal	Annals of Oncology
Volume	27
Issue number	4
DOIs	https://doi.org/10.1093/annonc/mdv577
Publication status	Published - Apr 2016

Keywords

HER2 imaging
HER2-positive breast cancer
prediction of T-DM1 efficacy

Access to Document

https://doi.org/10.1093/annonc/mdv577

Cite this

Gebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W. J. G., Vugts, D. J., Hoekstra, O. S., Schroder, C. P., van Oordt, C. W. M. D. H., Guiot, T., Brouwers, A. H., Awada, A., de Vries, E. G. E., & Flamen, P. (2016). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology, 27(4), 619-624. https://doi.org/10.1093/annonc/mdv577

@article{26aa6497ffc1414e816f9b4977326e0b,

title = "Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial",

keywords = "HER2 imaging, HER2-positive breast cancer, prediction of T-DM1 efficacy",

author = "G. Gebhart and Lamberts, {L. E.} and Z. Wimana and C. Garcia and P. Emonts and L. Ameye and S. Stroobants and M. Huizing and P. Aftimos and J. Tol and Oyen, {W. J. G.} and Vugts, {D. J.} and Hoekstra, {O. S.} and Schroder, {C. P.} and {van Oordt}, {C. W. Menke-van der Houven} and T. Guiot and Brouwers, {A. H.} and A. Awada and {de Vries}, {E. G. E.} and P. Flamen",

year = "2016",

month = apr,

doi = "https://doi.org/10.1093/annonc/mdv577",

language = "English",

volume = "27",

pages = "619--624",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "4",

}

Gebhart, G, Lamberts, LE, Wimana, Z, Garcia, C, Emonts, P, Ameye, L, Stroobants, S, Huizing, M, Aftimos, P, Tol, J, Oyen, WJG, Vugts, DJ , Hoekstra, OS, Schroder, CP, van Oordt, CWMDH, Guiot, T, Brouwers, AH, Awada, A, de Vries, EGE & Flamen, P 2016, 'Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial', Annals of Oncology, vol. 27, no. 4, pp. 619-624. https://doi.org/10.1093/annonc/mdv577

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. / Gebhart, G.; Lamberts, L. E.; Wimana, Z. et al.
In: Annals of Oncology, Vol. 27, No. 4, 04.2016, p. 619-624.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

AU - Gebhart, G.

AU - Lamberts, L. E.

AU - Wimana, Z.

AU - Garcia, C.

AU - Emonts, P.

AU - Ameye, L.

AU - Stroobants, S.

AU - Huizing, M.

AU - Aftimos, P.

AU - Tol, J.

AU - Oyen, W. J. G.

AU - Vugts, D. J.

AU - Hoekstra, O. S.

AU - Schroder, C. P.

AU - van Oordt, C. W. Menke-van der Houven

AU - Guiot, T.

AU - Brouwers, A. H.

AU - Awada, A.

AU - de Vries, E. G. E.

AU - Flamen, P.

PY - 2016/4

Y1 - 2016/4

KW - HER2 imaging

KW - HER2-positive breast cancer

KW - prediction of T-DM1 efficacy

U2 - https://doi.org/10.1093/annonc/mdv577

DO - https://doi.org/10.1093/annonc/mdv577

M3 - Article

C2 - 26598545

SN - 0923-7534

VL - 27

SP - 619

EP - 624

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -